With the approval of Tirzepatide (Zepbound) in late 2023, there has been a notable surge in interest and development within the anti-obesity drug market. Analysts project that this market could exceed US$ 100 billion by 2030. These medications, particularly innovative classes such as Tirzepatide, which is a dual receptor agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), exhibit significant potential for weight loss. Tirzepatide activates receptors of these intestinal hormones, thereby reducing appetite and food intake. This remarkable efficacy, however, prompts a critical inquiry: how will the emergence and proliferation of anti-obesity drugs influence the medical device market landscape? Furthermore, it raises the question of why there is a heightened focus on these drugs now, despite the existence of anti-obesity medications for over a century.
Read more: Data and Analytics in Healthcare: Benefits and its Importance
Anti-obesity drugs are not something new, with several molecules having been approved over the past few decades. Historically, these medications have been associated with a weight reduction of approximately 5-10%. However, recent advancements have led to the development of drugs that can achieve a more substantial weight loss, with some reporting an average reduction of around 25%. Eli Lilly’s Retatrutide, one of the most promising anti-obesity drugs currently in Phase III trials, demonstrated a 22.4% reduction in body weight over a 48-week period. Retatrutide has shown significant efficacy in reducing liver fat. It is also being investigated for its potential benefits in other conditions, including obstructive sleep apnea, knee osteoarthritis, and chronic kidney disease (CKD).
Wegovy was initially approved as an anti-obesity drug and also received additional approval in March 2024 to prevent life-threatening cardiovascular events in adults suffering from cardiovascular disease who are either obese or overweight. Retatrutide is also being investigated for its potential benefits in other conditions, including obstructive sleep apnea, knee osteoarthritis, and chronic kidney disease (CKD). These expanded indications could enhance the adoption of such drugs among the obese and overweight population, providing broader therapeutic benefits.
Emerging indications and their improved efficacy and non-invasive nature position anti-obesity drugs as preferred treatments. However, their short-term impact is tempered by challenges related to access and reimbursement, along with high out-of-pocket costs, as they could cost ~US$ 1,000 per month. Additionally, these therapies may cause gastrointestinal side effects, potentially impeding their near-term adoption.
In the US, reimbursement for anti-obesity drugs is contingent upon patients meeting specific BMI criteria. In March 2024, Medicare expanded coverage to include these drugs, providing evidence supporting their effectiveness in reducing conditions such as heart attacks and strokes. This policy change is expected to reduce long-term Medicare spending, highlighting its potential to mitigate healthcare costs over time.
Read more: Importance of Data Analytics in the Healthcare Industry
Impact on MedTech Industry
While the current impact on the medical device industry is not significant, any destructive impact is anticipated to occur gradually. Nevertheless, investor concerns are mounting. Companies such as ResMed, Inspire Medical Systems, Zimmer Biomet, and Smith+Nephew have seen declines in their valuations following the introduction of various anti-obesity drugs into the market. The potential areas of impact on the medical device industry include:
-
Bariatric Surgery
MedTech firms specializing in devices for bariatric surgery should anticipate that physicians will prioritize non-surgical interventions, potentially influencing market dynamics. However, there is a prospective benefit as GLP-1s may help more patients achieve BMI reductions necessary for bariatric device eligibility.
-
Orthopedics
Similarly, weight reduction may alleviate joint stress and potentially expand the pool of candidates for knee and hip replacements. Individuals without obesity will likely maintain consistent demand for joint replacements.
-
Cardiovascular Devices
Increasing evidence suggests GLP-1s can lower the incidence of heart attacks and strokes. For instance, findings from the SELECT trial demonstrated a 20% reduction in cardiovascular events with semaglutide among overweight or obese adults with established heart disease and without diabetes. The implications for cardiology practice remain uncertain and likely to be minimal for surgical devices in the near term.
-
Sleep Apnea Devices
Obesity is considered a leading risk factor for obstructive sleep apnea; weight loss could significantly decrease its prevalence and consequently reduce the demand for CPAP devices. Ongoing clinical trials examine this relationship, though the market’s future will depend on patient treatment trajectories and payer reimbursement policies.
Read more: Data & AI Solutions to Improve Patient Care and Healthcare Research
Conclusion
The emergence of novel anti-obesity drugs, such as Tirzepatide, represents a notable advancement with profound implications for healthcare sectors, heralding transformative shifts in treatment approaches and patient health outcomes. Despite existing challenges, such as reimbursement complexities and potential adverse effects, the expanding scope of therapeutic applications and supportive regulatory changes point toward a promising trajectory. Companies within the medical device industry should pivot to strategically integrate these pharmacological innovations into holistic healthcare strategies, leveraging synergies with their existing device solutions. This approach should prioritize enhancing patient outcomes and adept navigation of evolving market landscapes, securing enduring competitive advantages in the foreseeable future.
A leader in the healthcare domain, SG Analytics assists healthcare companies in leveraging the power of information. Contact us today if you are in search of efficient Healthcare solutions to make sound business decisions.
About SG Analytics
SG Analytics (SGA) is an industry-leading global data solutions firm providing data-centric research and contextual analytics services to its clients, including Fortune 500 companies, across BFSI, Technology, Media & Entertainment, and Healthcare sectors. Established in 2007, SG Analytics is a Great Place to Work® (GPTW) certified company with a team of over 1200 employees and a presence across the U.S.A., the UK, Switzerland, Poland, and India.
Apart from being recognized by reputed firms such as Gartner, Everest Group, and ISG, SGA has been featured in the elite Deloitte Technology Fast 50 India 2023 and APAC 2024 High Growth Companies by the Financial Times & Statista.
